Ginsenoside Rh2 Inhibits Angiogenesis in Prostate Cancer by Targeting CNNM1

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Prostate cancer remains a leading cause of cancer-related deaths.
• Targeting angiogenesis is a key strategy in cancer therapy.
• Ginsenoside Rh2 (G-Rh2) is a natural compound with potential anti-cancer properties.

Purpose of the Study:

• To elucidate the molecular mechanisms of G-Rh2 in inhibiting prostate cancer growth.
• To investigate the role of G-Rh2 in regulating tumor angiogenesis.
• To determine the involvement of CNNM1 in G-Rh2's anti-cancer effects.

Main Methods:

• In vivo studies using prostate cancer cell lines (LNCaP, PC3, DU145) xenografted in nude mice.
• In vitro co-culture assays with vascular endothelial cells to assess G-Rh2's effect on cell proliferation.
• Gene expression analysis (qRT-PCR, Western blot) of CD31, VEGF, PDGF, and CNNM1.
• Studies involving CNNM1 overexpression and knockout in cancer cells.

Main Results:

• G-Rh2 significantly inhibited prostate cancer cell growth and tumor volume in vivo (P <0.05).
• G-Rh2 reduced the proliferation of vascular endothelial cells co-cultured with prostate cancer cells (P <0.05).
• G-Rh2 decreased the expression of CD31, VEGF, PDGF, and CNNM1 in prostate cancer cells.
• CNNM1 overexpression reversed G-Rh2's inhibitory effect on CD31 expression, while CNNM1 knockout mimicked G-Rh2's inhibitory effect.

Conclusions:

• Ginsenoside Rh2 (G-Rh2) exhibits significant anti-prostate cancer activity.
• G-Rh2 inhibits angiogenesis by downregulating CNNM1 expression in prostate cancer cells.
• Targeting CNNM1 may represent a therapeutic strategy for G-Rh2-mediated prostate cancer treatment.